Acute Lymphoblastic Leukemia in Adolescents and Young Adults

Hematology/Oncology Clinics of North America

Volumn 23, Issue 5, 2009, Pages 1033-1042

  Ribera, Josep Maria ^a   Oriol, Albert ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Acute lymphoblastic; Adolescents; Leukemia; Treatment; Young adults

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINASE MACROGOL; CORTICOSTEROID; CYTARABINE; GLUCOCORTICOID; METHOTREXATE; PREDNISONE; VINCA ALKALOID; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADOLESCENT DISEASE; BONE NECROSIS; CLINICAL TRIAL; CYTOGENETICS; DIABETES MELLITUS; DOSE RESPONSE; DRUG MEGADOSE; GENE REARRANGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LOW DRUG DOSE; MOLECULAR GENETICS; ONSET AGE; PANCREATITIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; REVIEW; THROMBOEMBOLISM; THROMBOSIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SURVIVAL RATE; YOUNG ADULT;

EID: 70349929823     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.07.002     Document Type: Review

References (43)

1. Pui C.H., Robison L.L., and Look A.T. Acute lymphoblastic leukaemia. Lancet 371 9617 (2008) 1030-1043
2. Pulte D., Gondos A., and Brenner H. Trends in 5-and 10-year survival after diagnosis with childhood hematologic malignancies in the United States 1990-2004. J Natl Cancer Inst 100 18 (2008) 1271-1273
3. Gokbuget N., and Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 46 1 (2009) 64-75
4. Larson R., and Stock W. Progress in the treatment of adults with acute lymphoblastic leukemia. Curr Opin Hematol 15 4 (2008) 400-407
5. Ries LAL, Melbert D, Krapcho M, et al. Cancer statistics review, 1975-2005, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2005/.Accessed 2008.
6. Pullen J., Shuster J.J., Link M., et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 13 11 (1999) 1696-1707
7. Secker-Walker L.M., Craig J.M., Hawkins J.M., et al. Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 5 3 (1991) 196-199
8. Aguiar R.C., Sohal J., van Rhee F., et al. TEL-AML1 fusion in acute lymphoblastic leukaemia of adults. M.R.C. Adult Leukaemia Working Party. Br J Haematol 95 4 (1996) 673-677
9. Harrison C.J. Cytogenentics in paediatric and adolescents acute lymphoblastic leukaemia. Br J Haematol 144 2 (2009) 147-156
10. Dini G., Banov L., and Dini S. Were should adolescents with ALL be treated?. Bone Marrow Transplant 42 Suppl 2 (2008) S35-S39
11. Stock W., La M., Sanford B., et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 112 5 (2008) 1646-1674
12. Boissel N., Auclerc M.-F., Lheritier V., et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21 5 (2003) 774-780
13. de Bont J.M., van der Holt B., Dekker A.W., et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18 12 (2004) 2032-2035
14. Testi A.M., Valsecchi M.G., Conter V., et al. Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. [abstract]. Blood 104 (2004) 1954
15. Hallbook H., Gustafsson G., Smedmyr B., et al. Swedish Adult Acute Lymphocytic Leukemia Group, Swedish Childhood Leukemia Group. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 107 7 (2006) 1551-1561
16. Schroder H., Kjeldahl M., Boesen A.M., et al. Acute lymphoblastic leukemia in adolescents between 10 and 19 years of age in Denmark. Dan Med Bull 53 1 (2006) 76-79
17. Ramanujachar R., Richards S., Hann I., et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48 6 (2007) 254-261
18. Lopez-Hernandez M.A., Alvarado-Ibarra M., Jiménez-Alvarado R.M., et al. Adolescents with de novo acute lymphoblastic leukemia: efficacy and safety of a pediatric vs. adult treatment protocol. Gac Med Mex 144 6 (2008) 485-489
19. Usvasalo A., Räty R., Knuutila S., et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 93 8 (2008) 1161-1168
20. Schiffer C.A. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?. J Clin Oncol 21 5 (2003) 760-761
21. Sallan S.E. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program (2006) 128-132
22. Webb DKH. Management of adolescents with acute lymphoblastic leukemia: implications for adult therapy. Hematology Education. The Education Programme for the 13th Congress of the European Hematology Association 2008;2:71-5.
23. Seibel N. Treatment of acute lymphoblastic leukemia in children and adolescents: peaks and pitfalls. Hematology Am Soc Hematol Educ Program (2008) 374-380
24. Peters C., Schrander A., Schrappe M., et al. Allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia: the BFM/IBFMEBMT concepts. Bone Marrow Transplant 35 Suppl 1 (2005) S9-11
25. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111 4 (2008) 1827-1833
26. Burke M.E., Albriton K., and Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 110 11 (2007) 2385-2393
27. Kantarjian H.M., and O'Brien S. Insurance policies in the United States may explain part of the outcome differences of adolescents and young adults with acute lymphoblastic leukemia treated on adult versus pediatric regimens. [letter]. Blood 113 8 (2009) 1861
28. Barry E., DeAngelo D.J., Neuberg D., et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana Farber Cancer Institute ALL Consortium protocols. J Clin Oncol 25 7 (2007) 813-819
29. Ribera J.M., Oriol A., Sanz M.A., et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the pediatric-based protocol PETHEMA ALL-96. J Clin Oncol 26 11 (2008) 1843-1849
30. Huguet F., Raffoux E., Thomas X., et al. Pediatric inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL/2003 study. J Clin Oncol 27 1 (2009) 911-918
31. DeAngelo D.J., Silverman L.B., Couban S., et al. A multicenter phase II study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukaemia. [abstract]. Blood 108 (2006) 526
32. Storring J.M., Brandwein J., Gupta V., et al. Treatment of adult acute lymphoblastic leukaemia (ALL) with a modified DFCI pediatric regimen. The Princess Margaret experience. [abstract]. Blood 108 (2006) 316
33. Srivastava P., Watkins K., Mark L., et al. Treatment of adults with newly diagnosed acute lymphoblastic leukemia with multiple doses of intravenous pegylated asparaginase in an intensified pediatric regimen. [abstract]. Haematologica 93 s1 (2008) 366
34. Appel I.M., Kazemier K.M., Boos J., et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 22 9 (2008) 1665-1679
35. Wetzler M., Sanford B.L., Kurtzberg J., et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study. Blood 109 10 (2007) 4164-4167
36. Zeidan A., Wang E.S., and Wetzler M. Pegasparaginase: where do we stand?. Expert Opin Biol Ther 9 1 (2009) 111-119
37. Balduzzi A., Valsecchi M.G., Uderzo C., et al. Chemotherapy versus allogeneic transplantation for very-high-risk childhood acute lymphoblastic leukaemia in first complete remission: comparison by genetic randomisation in an international prospective study. Lancet 366 9486 (2005) 635-642
38. Ribera J.M., Ortega J.J., Oriol A., et al. Comparison of intensive chemotherapy, allogeneic, or autologous stem-cell transplantation as postremission treatment for children with very high risk acute lymphoblastic leukemia: PETHEMA ALL-93 Trial. Clin Oncol 25 1 (2007) 16-24
39. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 46 1 (2009) 100-106
40. Raff T., Gokbuget N., Luschen S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 109 3 (2007) 910-915
41. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukaemia. Blood 107 3 (2006) 116-123
42. Bassan R., Spinelli O., Oldani E., et al. Improved risk classification for risk-specific therapy based on the molecular study of MRD in adult ALL. Blood 113 18 (2009) 4153-4162
43. Reynolds B.C., Windebank K.P., Leonard R.C., et al. A comparison of self-reported satisfaction between adolescents treated in a 'teenage' unit with those treated in adult or paediatric units. Pediatr Blood Cancer 44 3 (2005) 259-263